FCCC LOGO Faculty Publications
Siddiqui F , Pajak TF , Watkins-Bruner D , Konski AA , Coyne JC , Gwede CK , Garden AS , Spencer SA , Jones C , Movsas B
Pretreatment quality of life predicts for locoregional control in head and neck cancer patients: A radiation therapy oncology group analysis
International Journal of Radiation Oncology Biology Physics. 2008 Feb;70(2) :353-360
PMID: ISI:000252521700005   
Back to previous list
Abstract
Purpose: To analyze the prospectively collected health-related quality-of-life (HRQOL) data from patients enrolled in two Radiation Therapy Oncology Group randomized Phase III head and neck cancer trials (90-03 and 91-11) to assess their value as an independent prognostic factor for locoregional control (LRC) and/or overall survival (OS). Methods and Materials: HRQOL questionnaires, using a validated instrument, the Functional Assessment of Cancer Therapy-Head and Neck (FACT-H&N), version 2, were completed by patients before the start of treatment. OS and LRC were the outcome measures analyzed using a multivariate Cox proportional hazard model. Results: Baseline FACT-H&N data were available for 1,093 patients and missing for 417 patients. No significant difference in outcome was found between the patients with and without baseline FACT-H&N data (p = 0.58). The median follow-up time was 27.2 months for all patients and 49 months for surviving patients. Multivariate analyses were performed for both OS and LRC. Beyond tumor and nodal stage, Karnofsky performance status, primary site, cigarette use, use of concurrent chemotherapy, and altered fractionation schedules, the FACT-H&N score was independently predictive of LRC (but not OS), with p = 0.0038. The functional well-being component of the FACT-H&N predicted most significantly for LRC (p = 0.0004). Conclusions: This study represents, to our knowledge, the largest analysis of HRQOL as a prognostic factor in locally advanced head and neck cancer patients. The results of this study have demonstrated the importance of baseline HRQOL as a significant and independent predictor of LRC in patients with locally advanced head and neck cancer. (C) 2008 Elsevier Inc.
Notes
ISI Document Delivery No.: 253MG Times Cited: 0 Cited Reference Count: 35 Cited References: BASENENGQUIST K, 2001, J CLIN ONCOL, V19, P1809 BERNHARD J, 1996, BRIT J CANCER, V74, P1660 BRADY MJ, 1997, J CLIN ONCOL, V15, P974 BUCCHERI GF, 1995, LUNG CANCER, V12, P45 CELLA DF, 1993, J CLIN ONCOL, V11, P570 CELLA DF, 1995, LUNG CANCER, V12, P199 COATES A, 1997, EUR J CANCER, V33, P1025 COLLETTE L, 2004, J CLIN ONCOL, V22, P3877 COYNE JC, 2004, PSYCHOSOM MED, V66, A36 DEBOER MF, 1998, CANCER, V83, P2567 DEGRAEFF A, 2001, EUR J CANCER, V37, P332 EFFICACE F, 2004, EUR J CANCER, V40, P1021 EFFICACE F, 2004, J CLIN ONCOL, V22, P3381 ESPER P, 1997, UROLOGY, V50, P920 FANG FM, 2004, CANCER, V100, P425 FORASTIERE AA, 2003, NEW ENGL J MED, V349, P2091 FU KK, 2000, INT J RADIAT ONCOL, V48, P7 HEFFERNAN N, 2002, J CLIN ONCOL, V20, P2229 HERNDON JE, 1999, CANCER, V85, P333 KAASA S, 1989, RADIOTHER ONCOL, V15, P235 KONSKI A, 2006, INT J RADIAT ONCOL, V66, P229 KONSKI AA, 2006, J CLIN ONCOL, V24, P4177 KRAMER JA, 2000, EUR J CANCER, V36, P1498 LANGENDIJK H, 2000, RADIOTHER ONCOL, V55, P19 LIST MA, 1996, CANCER, V77, P2294 MAIONE P, 2005, J CLIN ONCOL, V23, P6865 MONTAZERI A, 2001, LUNG CANCER-J IASLC, V31, P233 MOVSAS B, 2006, INT J RADIAT ONCOL, V65, P830 OSOBA D, 1996, CANCER TREAT REV A, V22, P69 RUCKDESCHEL JC, 1994, CHEST, V106, S324 SIDDIQUI F, 2006, HEMATOL ONCOL CLIN N, V20, P165 WADSLEY JC, 2004, INT J RADIAT ONCOL, V60, P1405 WARD WL, 1999, QUAL LIFE RES, V8, P181 WATKINSBRUNER D, 1995, INT J RADIAT ONCOL, V33, P901 WEITZNER MA, 1995, CANCER, V75, P1151 Siddiqui, Farzan Pajak, Thomas F. Watkins-Bruner, Deborah Konski, Andre A. Coyne, James C. Gwede, Clement K. Garden, Adam S. Spencer, Sharon A. Jones, Christopher Movsas, Benjamin ELSEVIER SCIENCE INC; 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA